AbbVie (ABBV) is back in focus after the European Commission approved Tepkinly plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, putting fresh attention on how this oncology franchise fits into the stock’s current valuation.

Against this backdrop of Tepkinly’s European approval, other positive trial readouts and recent index inclusions, AbbVie’s momentum has been strong, with a 30 day share price return of 12.07% and a 1 year total shareholder return of 38.56%.

If you are looking beyond AbbVie’s oncology and immunology pipeline for additional ideas, this could be a useful moment to scan other healthcare opportunities using the 40 healthcare AI stocks

After a 12.1% 30 day jump that leaves AbbVie trading close to a US$258.32 analyst target but at a large discount to some intrinsic value estimates, the next step is clear: how much upside do current valuation frameworks still suggest?

Most Popular Narrative: 0% Overvalued

AbbVie’s last close at $254.65 sits almost exactly on top of the most followed fair value estimate of $253.55. This narrative treats the stock as essentially fully priced while still tying that view to specific earnings, margin and valuation assumptions.

Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.

Want to understand why this fair value leans so heavily on rising margins and faster earnings than revenue, capped by a higher future P/E than the sector? The narrative walks through the revenue build, the profit step up and the valuation multiple it needs to tie together.

Result: Fair Value of $253.55 (ABOUT RIGHT)

However, AbbVie’s reliance on a concentrated immunology and neuroscience portfolio, combined with ongoing drug pricing and regulatory pressures, could still upset those margin heavy earnings assumptions.

Another View: AbbVie Through a Cash Flow Lens

The analyst narrative effectively treats AbbVie as fairly valued around $253.55, yet the SWS DCF model points in a different direction, with an estimated future cash flow value of $457.98 per share that is 44.4% above the current $254.65 price. Which perspective do you think fits AbbVie better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AbbVie for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals in this AbbVie story leave you unsure, take a closer look at the underlying data and act quickly to shape your own view with the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond AbbVie?

If AbbVie has sharpened your interest in healthcare and income opportunities, do not stop here. Use these focused tools to uncover other stocks that fit your goals.

• Target resilient income by reviewing potential high yield candidates through the 9 dividend fortresses.
• Hunt for mispriced quality by scanning companies that appear out of favor using the 45 high quality undervalued stocks.
• Prioritize capital preservation by filtering for companies with steadier profiles via the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.